Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies

Supportive Care in Cancer

Volumn 24, Issue 12, 2016, Pages 4887-4894

  Efficace, Fabio ^a   Breccia, Massimo ^b   Cottone, Francesco ^a   Okumura, Iris ^c   Doro, Maribel ^c   Riccardi, Francesca ^d   Rosti, Gianantonio ^e   Baccarani, Michele ^e  

^a Italian Group for Adult Hematologic Diseases (GIMEMA)   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic myeloid leukemia; Leukemia; Psychological well being; Social support; Target therapy; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MULTIDIMENSIONAL SCALE OF PERCEIVED SOCIAL SUPPORT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGICAL GENERAL WELL BEING INDEX; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGICAL WELL-BEING; PSYCHOMETRY; SELF CONTROL; SEX DIFFERENCE; SOCIAL NORM; SOCIAL SUPPORT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PSYCHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; SOCIAL SUPPORT; YOUNG ADULT;

EID: 84979503823     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-016-3344-6     Document Type: Article

References (38)

1. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004. doi:10.1056/NEJMoa022457
2. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Dobrez DG, Hensley ML, Cella D (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 21(11):2138–2146. doi:10.1200/JCO.2003.12.154
3. Cortes J, Hochhaus A, Hughes T, Kantarjian H (2011) Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 29(5):524–531. doi:10.1200/JCO.2010.31.3619
4. Gambacorti-Passerini C, Antolini L, Mahon F-X, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D’Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim D-W (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. JNCI 103(7):553–561
5. Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M (2015) Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 29(9):1823–1831. doi:10.1038/leu.2015.152
6. Hochhaus A (2011) Managing chronic myeloid leukemia as a chronic disease. American society of hematology educational program book. Hematology 128–135. doi:10.1182/asheducation-2011.1.128
7. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388. doi:10.1200/JCO.2009.26.3087
8. Cella D, Nowinski CJ, Frankfurt O (2014) The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology 87(3):133–147. doi:10.1159/000362816
9. Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ (2014) Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin 30(11):2317–2328. doi:10.1185/03007995.2014.944973
10. Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23(3):825–836. doi:10.1007/s11136-013-0523-5
11. Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Barate C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554–4560
12. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884. doi:10.1182/blood-2013-05-501569
13. Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB (2013) Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 21(4):1097–1103. doi:10.1007/s00520-012-1630-5
14. Berkman LF, Glass T, Brissette I, Seeman TE (2000) From social integration to health: Durkheim in the new millennium. Soc Sci Med 51(6):843–857
15. Gonzalez-Saenz de Tejada M, Bilbao A, Bare M, Briones E, Sarasqueta C, Quintana JM, Escobar A (2015) Association of social support, functional status, and psychological variables with changes in health-related quality of life outcomes in patients with colorectal cancer. Psychooncology. doi:10.1002/pon.4022
16. Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I (2006) Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol 24(7):1105–1111. doi:10.1200/JCO.2005.04.2846
17. Cicero V, Lo Coco G, Gullo S, Lo Verso G (2009) The role of attachment dimensions and perceived social support in predicting adjustment to cancer. Psychooncology 18(10):1045–1052. doi:10.1002/pon.1390
18. Lim JW, Zebrack B (2006) Social networks and quality of life for long-term survivors of leukemia and lymphoma. Support Care Cancer 14(2):185–192. doi:10.1007/s00520-005-0856-x
19. Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, Chie W, Naeem A, Nicolatou-Galitis O, Cocks K, Vignetti M, Baccarani M, Mandelli F, Sprangers M (2012) Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?: GIMEMA and EORTC quality of life group. Ann Hematol 91(9):1371–1381. doi:10.1007/s00277-012-1458-6
20. Grossi E, Groth N, Mosconi P, Cerutti R, Pace F, Compare A, Apolone G (2006) Development and validation of the short version of the psychological general well-being index (PGWB-S). Health Qual Life Outcomes 4:88. doi:10.1186/1477-7525-4-88
21. Dupuy HJ (1984). (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CD, Elinson J (eds) Assessment of Quality of Life in clinical trials of cardiovascular therapies. Le Jacq Publishing. 9:170–183
22. Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA (1990) Psychometric characteristics of the multidimensional scale of perceived social support. J Pers Assess 55(3–4):610–617. doi:10.1080/00223891.1990.9674095
23. Grassi L, Rasconi G, Pedriali A, Corridoni A, Bevilacqua M (2000) Social support and psychological distress in primary care attenders. Ferrara SIMG group. Psychother Psychosom 69(2):95–100
24. Cormio C, Romito F, Giotta F, Mattioli V (2015) Post-traumatic growth in the Italian experience of long-term disease-free cancer survivors. Stress Health 31(3):189–196. doi:10.1002/smi.2545
25. Grossi E, Mosconi P., Groth N., Niero M., Apolone G. Questionario psychological general well-being index. Versione Italiana. Istituto di Ricerche Farmacologiche “Mario Negri” Milano. Maggio 2002 http://crc.marionegri.it/qdv/downloads/PGWBI_Manuale.pdf. pp. 31–42.
26. Brix C, Schleussner C, Fuller J, Roehrig B, Wendt TG, Strauss B (2008) The need for psychosocial support and its determinants in a sample of patients undergoing radiooncological treatment of cancer. J Psychosom Res 65(6):541–548. doi:10.1016/j.jpsychores.2008.05.010
27. Lindberg P, Koller M, Steinger B, Lorenz W, Wyatt JC, Inwald EC, Klinkhammer-Schalke M (2015) Breast cancer survivors’ recollection of their illness and therapy seven years after enrolment into a randomised controlled clinical trial. BMC Cancer 15:554. doi:10.1186/s12885-015-1573-6
28. Sapp AL, Trentham-Dietz A, Newcomb PA, Hampton JM, Moinpour CM, Remington PL (2003) Social networks and quality of life among female long-term colorectal cancer survivors. Cancer 98(8):1749–1758. doi:10.1002/cncr.11717
29. Holland KD, Holahan CK (2003) The relation of social support and coping to positive adaptation to breast cancer. Psychol Health. 18:15–29
30. Vehling S, Mehnert A, Hartmann M, Oing C, Bokemeyer C, Oechsle K (2015) Anxiety and depression in long-term testicular germ cell tumor survivors. Gen Hosp Psychiatry. doi:10.1016/j.genhosppsych.2015.09.001
31. Avis NE, Levine B, Naughton MJ, Case DL, Naftalis E, Van Zee KJ (2012) Explaining age-related differences in depression following breast cancer diagnosis and treatment. Breast Cancer Res Treat 136(2):581–591. doi:10.1007/s10549-012-2277-0
32. Vinokur AD, Threatt BA, Vinokur-Kaplan D, Satariano WA (1990) The process of recovery from breast cancer for younger and older patients. Changes during the first year. Cancer 65(5):1242–1254
33. Krebber AM, Buffart LM, Kleijn G, Riepma IC, de Bree R, Leemans CR, Becker A, Brug J, van Straten A, Cuijpers P, Verdonck-de Leeuw IM (2014) Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psycho-Oncology 23(2):121–130. doi:10.1002/pon.3409
34. Pashos CL, Flowers CR, Kay NE, Weiss M, Lamanna N, Farber C, Lerner S, Sharman J, Grinblatt D, Flinn IW, Kozloff M, Swern AS, Street TK, Sullivan KA, Harding G, Khan ZM (2013) Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer 21(10):2853–2860. doi:10.1007/s00520-013-1854-z
35. Drost FM, Mols F, Kaal SE, Stevens WB, van der Graaf WT, Prins JB, Husson O (2016) Psychological impact of lymphoma on adolescents and young adults: not a matter of black or white. J Cancer Surv. doi:10.1007/s11764-016-0518-7
36. Korszun A, Sarker SJ, Chowdhury K, Clark C, Greaves P, Johnson R, Kingston J, Levitt G, Matthews J, White P, Lister A, Gribben J (2014) Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. Br J Haematol 164(6):790–803. doi:10.1111/bjh.12698
37. Morotti A, Fava C, Saglio G (2015) Milestones and monitoring. Curr Hematol Malig Rep 10(2):167–172. doi:10.1007/s11899-015-0258-1
38. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63(2):789–799